{"title":"印度乳腺癌患者护理途径与延迟获得医疗服务的混合方法研究","authors":"Radhika Kuthari, Raman Damor, Kalpita Shringarpure","doi":"10.31557/APJCP.2025.26.6.2097","DOIUrl":null,"url":null,"abstract":"<p><p>Delay in receiving treatment or untimely discontinuation can impact patient survival. This study addresses the literature gap in knowledge about care pathway of patients following initiation of treatment, quantifies the delays in obtaining healthcare services and explores the challenges faced by them in this process.</p><p><strong>Methods: </strong>A concurrent triangulation mixed method study was conducted. All breast cancer patients above 18 years, who were aware of their diagnosis and whose treatment had commenced were included with their consent. The final sample size was 150. Patient pathway was documented through in-depth interviews and delay in access, diagnosis, and various treatment modalities was quantified after reviewing patient records. Factors associated with overall delay (from onset of symptoms to initiation of treatment) were identified by bivariate analysis. Inductive thematic analysis of interviews was done to identify reasons for delay.</p><p><strong>Results: </strong>Of 150 patients, 111 (74%) consulted at least two healthcare facilities and 75 (50%) consulted only government facilities during their treatment. Majority, 124 (82.6%) patients faced delay in their care pathway; 88 (58.6%) experienced overall delay (median duration 109 days) which was significantly associated with patient's education and caregiver's occupation (p<0.05), and 48 (32%) out of 149 women were delayed in initiation of chemotherapy. Median access, diagnostic and treatment interval were 60 days, 20 days, and 6 days respectively. Median duration between surgery and chemotherapy, and surgery and radiotherapy was 10 days and 139 days respectively. The major themes that emerged in access delay were neglect, avoidance, and reliance on family. Diagnostic delay included themes of misdiagnosis and difficulty in navigating healthcare systems. Treatment delay included themes of misconceptions, avoidance, neglect, and affordability and accessibility of services.</p><p><strong>Conclusion: </strong>Majority of the patients visited at least two facilities and experienced delay in receiving healthcare services. Both patient and provider side challenges were responsible for delay.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"2097-2107"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mixed Methods Study of Care Pathway and Delay in Obtaining Health Services by Breast Cancer Patients in India.\",\"authors\":\"Radhika Kuthari, Raman Damor, Kalpita Shringarpure\",\"doi\":\"10.31557/APJCP.2025.26.6.2097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Delay in receiving treatment or untimely discontinuation can impact patient survival. This study addresses the literature gap in knowledge about care pathway of patients following initiation of treatment, quantifies the delays in obtaining healthcare services and explores the challenges faced by them in this process.</p><p><strong>Methods: </strong>A concurrent triangulation mixed method study was conducted. All breast cancer patients above 18 years, who were aware of their diagnosis and whose treatment had commenced were included with their consent. The final sample size was 150. Patient pathway was documented through in-depth interviews and delay in access, diagnosis, and various treatment modalities was quantified after reviewing patient records. Factors associated with overall delay (from onset of symptoms to initiation of treatment) were identified by bivariate analysis. Inductive thematic analysis of interviews was done to identify reasons for delay.</p><p><strong>Results: </strong>Of 150 patients, 111 (74%) consulted at least two healthcare facilities and 75 (50%) consulted only government facilities during their treatment. Majority, 124 (82.6%) patients faced delay in their care pathway; 88 (58.6%) experienced overall delay (median duration 109 days) which was significantly associated with patient's education and caregiver's occupation (p<0.05), and 48 (32%) out of 149 women were delayed in initiation of chemotherapy. Median access, diagnostic and treatment interval were 60 days, 20 days, and 6 days respectively. Median duration between surgery and chemotherapy, and surgery and radiotherapy was 10 days and 139 days respectively. The major themes that emerged in access delay were neglect, avoidance, and reliance on family. Diagnostic delay included themes of misdiagnosis and difficulty in navigating healthcare systems. Treatment delay included themes of misconceptions, avoidance, neglect, and affordability and accessibility of services.</p><p><strong>Conclusion: </strong>Majority of the patients visited at least two facilities and experienced delay in receiving healthcare services. Both patient and provider side challenges were responsible for delay.</p>\",\"PeriodicalId\":55451,\"journal\":{\"name\":\"Asian Pacific Journal of Cancer Prevention\",\"volume\":\"26 6\",\"pages\":\"2097-2107\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific Journal of Cancer Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31557/APJCP.2025.26.6.2097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.6.2097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Mixed Methods Study of Care Pathway and Delay in Obtaining Health Services by Breast Cancer Patients in India.
Delay in receiving treatment or untimely discontinuation can impact patient survival. This study addresses the literature gap in knowledge about care pathway of patients following initiation of treatment, quantifies the delays in obtaining healthcare services and explores the challenges faced by them in this process.
Methods: A concurrent triangulation mixed method study was conducted. All breast cancer patients above 18 years, who were aware of their diagnosis and whose treatment had commenced were included with their consent. The final sample size was 150. Patient pathway was documented through in-depth interviews and delay in access, diagnosis, and various treatment modalities was quantified after reviewing patient records. Factors associated with overall delay (from onset of symptoms to initiation of treatment) were identified by bivariate analysis. Inductive thematic analysis of interviews was done to identify reasons for delay.
Results: Of 150 patients, 111 (74%) consulted at least two healthcare facilities and 75 (50%) consulted only government facilities during their treatment. Majority, 124 (82.6%) patients faced delay in their care pathway; 88 (58.6%) experienced overall delay (median duration 109 days) which was significantly associated with patient's education and caregiver's occupation (p<0.05), and 48 (32%) out of 149 women were delayed in initiation of chemotherapy. Median access, diagnostic and treatment interval were 60 days, 20 days, and 6 days respectively. Median duration between surgery and chemotherapy, and surgery and radiotherapy was 10 days and 139 days respectively. The major themes that emerged in access delay were neglect, avoidance, and reliance on family. Diagnostic delay included themes of misdiagnosis and difficulty in navigating healthcare systems. Treatment delay included themes of misconceptions, avoidance, neglect, and affordability and accessibility of services.
Conclusion: Majority of the patients visited at least two facilities and experienced delay in receiving healthcare services. Both patient and provider side challenges were responsible for delay.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.